Engelbert Catherine M. 4

What Happened

• Catherine M. Engelbert, a director of Royalty Pharma plc (RPRX), was awarded 4,545 restricted stock units (RSUs) on 2026-06-05. The award was reported as acquired at $0.00 (no cash paid), so the reported transaction value is $0. This is an equity award (transaction code A), not a purchase or sale.

Key Details

• Transaction date: 2026-06-05. Report filed with the SEC on 2026-06-08 (timely under Form 4 rules).
• Price: $0.00 per share; total cash consideration reported = $0.
• Shares issued/granted: 4,545 RSUs.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The RSUs were granted under the Issuer’s 2020 Independent Director Equity Incentive Plan and generally vest 100% on the earlier of (i) the one-year anniversary of the grant or (ii) the date of the annual meeting of shareholders in the first calendar year after the grant, subject to the plan and award agreement.

Context

• RSUs are restricted awards that typically convert into actual shares only upon vesting; they represent director compensation rather than an open-market purchase. Such grants are routine and do not, by themselves, indicate a buy/sell signal from the insider.